Find More Contacts for Versanis Bio
Protected Content
Chief Medical Officer, Executive VP
Non-Management, Executive Operations
1 email found 1 phone number found
View contacts for Versanis Bio to access new leads and connect with decision-makers.
View All Contacts

Details

Edit Details Section
  • Company Type For Profit
  • Contact Email info@versanisbio.com
  • Phone Number (617) 315-4410

Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled

clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.

Lists Featuring This Company

Edit Lists Featuring This Company Section
Hedge Fund Funded Companies
6,230 Number of Organizations • $1.6T Total Funding Amount • 74,933 Number of Investors
Private United States Companies (Top 10K)
9,931 Number of Organizations • $1.3T Total Funding Amount • 95,614 Number of Investors
Western US Companies (Top 10K)
9,944 Number of Organizations • $1.7T Total Funding Amount • 88,819 Number of Investors
West Coast Biotechnology Companies
5,284 Number of Organizations • $271.8B Total Funding Amount • 13,104 Number of Investors

M&A Details

Edit M&A Details Section
Versanis Bio was acquired by Eli Lilly for $1.9B on Jul 13, 2023. This deal was done in Cash.

Frequently Asked Questions

Edit Frequently Asked Questions Section
Where is Versanis Bio's headquarters? Versanis Bio is located in Oakland, California, United States.Who invested in Versanis Bio? Versanis Bio has 4 investors including Aditum Bio and TCG Crossover.How much funding has Versanis Bio raised to date? Versanis Bio has raised
$70M
.When was the last funding round for Versanis Bio? Versanis Bio closed its last funding round on Aug 31, 2021 from a Series A round.Who are Versanis Bio's competitors? Alternatives and possible competitors to Versanis Bio may include Carisma Therapeutics, Vivodyne, and Arctic Therapeutics.